UBS Group Lowers Charles River Laboratories Intl. (NYSE:CRL) Price Target to $145.00

Charles River Laboratories Intl. (NYSE:CRL) had its price target cut by analysts at UBS Group from $147.00 to $145.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The firm presently has a “neutral” rating on the medical research company’s stock. UBS Group’s price objective would indicate a potential upside of 11.10% from the stock’s previous close.

Several other analysts also recently commented on the company. SunTrust Banks raised their target price on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Zacks Investment Research downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Credit Suisse Group set a $138.00 target price on Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Friday, September 13th. Finally, Bank of America downgraded Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 target price for the company. in a research note on Friday, October 18th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $150.50.

Charles River Laboratories Intl. stock traded up $3.14 during trading hours on Thursday, reaching $130.51. 318,713 shares of the company’s stock were exchanged, compared to its average volume of 360,739. The company has a quick ratio of 1.38, a current ratio of 1.59 and a debt-to-equity ratio of 1.47. The firm’s 50 day simple moving average is $132.15 and its 200 day simple moving average is $133.41. Charles River Laboratories Intl. has a twelve month low of $103.00 and a twelve month high of $149.07. The firm has a market capitalization of $6.23 billion, a PE ratio of 21.64, a PEG ratio of 2.00 and a beta of 1.08.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $1.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.64 by $0.05. The company had revenue of $668.00 million during the quarter, compared to the consensus estimate of $674.08 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same period last year, the business posted $1.53 EPS. Analysts anticipate that Charles River Laboratories Intl. will post 6.53 EPS for the current year.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the transaction, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Great Lakes Advisors LLC boosted its stake in Charles River Laboratories Intl. by 3.2% during the 3rd quarter. Great Lakes Advisors LLC now owns 99,990 shares of the medical research company’s stock valued at $13,236,000 after purchasing an additional 3,071 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in Charles River Laboratories Intl. by 11.0% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,007,750 shares of the medical research company’s stock valued at $133,396,000 after purchasing an additional 99,900 shares during the last quarter. Eqis Capital Management Inc. boosted its stake in Charles River Laboratories Intl. by 37.2% during the 3rd quarter. Eqis Capital Management Inc. now owns 5,339 shares of the medical research company’s stock valued at $707,000 after purchasing an additional 1,448 shares during the last quarter. BBVA USA Bancshares Inc. boosted its stake in Charles River Laboratories Intl. by 16.4% during the 3rd quarter. BBVA USA Bancshares Inc. now owns 6,627 shares of the medical research company’s stock valued at $878,000 after purchasing an additional 935 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Charles River Laboratories Intl. by 31.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 229,047 shares of the medical research company’s stock valued at $30,319,000 after purchasing an additional 54,841 shares during the last quarter. Institutional investors and hedge funds own 94.31% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: How can investors find ex-dividend dates?

Stock Target Advisor

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.